Abstract
Purpose: Tanezumab, a nerve growth factor antibody, is being developed to relieve the signs and symptoms of osteoarthritis (OA). This subgroup analysis explored the efficacy of subcutaneous tanezumab in patients with OA of different radiographic severities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have